Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
March 25, 2008

Nanobac to Use BioChemics’ Delivery Technology with Prostatitis Compounds

  • Nanobac Pharmaceuticals will utilize BioChemics’ (BCI) drug delivery technology, Vale®, for the transdermal delivery of its prostatitis compounds. Terms of the deal include upfront payments already made, future fees, R&D support, as well as milestones.
  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.